-
Administrative Frequency of Alopecia Areata and Clinical Characteristics in a Colombian HMO: a Real-World Data Characterization For 2015-2023
Mar 10, 2025, 14:00 PM -
Methodology for Estimating Equal Value Life-Year for Standard Three-State Partitioned Survival Models
Mar 10, 2025, 14:00 PM -
The Role of Productivity Measures in Economic Evaluations of Migraine Therapies
Mar 10, 2025, 14:00 PM -
Drivers of Variability Exploration (DiVE!): A Review to Inform a Proposed Observational Study Evidence Synthesis and Reporting Checklist
Mar 10, 2025, 14:00 PM -
Budget Impact Analysis of Smart Infusion Pumps With Dedicated Equipment vs. Pumps With Basic Programming in Infusion Therapy in ICU
Mar 10, 2025, 14:00 PM -
Association between Exposure to GLP-1 Treatment and Pancreatitis Risk in Obesity Patients: A Retrospective Database Study
Mar 10, 2025, 14:00 PM -
The Impact of Family Spillover Effects in Economic Evaluation for SMA Type 1 Treatments in the United States
Mar 10, 2025, 14:00 PM -
Natural History and Burden of Disease Among Patients With Juvenile GM2 Gangliosidoses in France
Mar 10, 2025, 14:00 PM -
Renal Cell Carcinoma and Muscle Invasive Bladder Cancer Patients' Perception of Risk and Fear of Recurrence
Mar 10, 2025, 14:00 PM -
PICC Line (PICC) or Central Inserted Venous Catheter (CICC ) in Cancer Patients: Comparative Effectiveness and Cost-Effectiveness Analysis in Brasil/LATAM/LMIC
Mar 10, 2025, 14:00 PM -
Developing and Evaluating Definitions of Real-World (rw) Clinical Endpoints for Patients with Early-Stage Triple Negative Breast Cancer (esTNBC) Using a US Secondary Database
Mar 10, 2025, 14:00 PM -
Evaluation of Availability, Prices, and Affordability of Medicines for Hepatitis B and Hepatitis C Viruses at Community Pharmacies in a Senatorial District in North-Central Nigeria
Mar 10, 2025, 14:00 PM -
Adverse Events: Does Experience Impact Preferences? A Review of the Literature
Mar 10, 2025, 14:00 PM -
Bridging the Gap between the NAPOLI 3 Trial and Real-World Practice: Real-World Overall Survival (OS) of First-Line (1L) FOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Mar 10, 2025, 14:00 PM -
Variables Statistically Associated With Mental Health Among United States Adults With Asthma in the Medical Expenditure Panel Survey
Mar 10, 2025, 14:00 PM -
Real-World Healthcare Resource Utilization and Costs Associated with Elranatamab Initiation in Multiple Myeloma: the ALTITUDE-1 Study
Mar 10, 2025, 14:00 PM -
Landscape of Patient-Reported Outcomes Measures (PROMs) in Oncology Trials: Key Insights Into Patient Voice and Value
Mar 10, 2025, 14:00 PM -
Validity of Diagnostic Codes to Identify Metastatic Prostate Cancer in Medicare Claims Database
Mar 10, 2025, 14:00 PM -
Estimation of Drug Cost Reductions by Introducing formularies for An Employment-based Health Insurance Plan : A Simulation Using “Wellness-Star☆” Health Insurance Claims Database
Mar 10, 2025, 14:00 PM -
How Have Canada's Drug Agency Guidelines Impacted Choice of Model Structure and Use of Partitioned Survival Models in Oncology Submissions?
Mar 10, 2025, 14:00 PM